These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37671741)

  • 21. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.
    Huang J; Phillips S; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Jagasia M; Kassim A; Rawling KT; Savani BN; Sengsayadeth S; Cornell RF
    Bone Marrow Transplant; 2018 Jun; 53(6):701-707. PubMed ID: 29703965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Houde CA, Khan A, Jacobus SJ, et al. Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus Rvd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (Pts) with newly diagnosed multiple myeloma (NDMM) in the Determination phase 3 trial [abstract]. Blood. 2023;142(suppl 1):4762.
    Blood; 2024 Jun; 143(25):2676. PubMed ID: 38900470
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
    Sidana S; Kumar S; Fraser R; Estrada-Merly N; Giralt S; Agrawal V; Anderson LD; Aljurf M; Banerjee R; Bashey A; Battiwalla M; Beitinjaneh A; Chakraborty R; Chhabra S; Dhakal B; Dholaria B; Hashmi S; Janakiram M; Lee C; Lekakis L; Murthy HS; Parrondo R; Wangjam T; Usmani S; Shah N; Qazilbash M; D'Souza A
    Transplant Cell Ther; 2022 Feb; 28(2):83.e1-83.e9. PubMed ID: 34781066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
    Attal M; Lauwers-Cances V; Hulin C; Leleu X; Caillot D; Escoffre M; Arnulf B; Macro M; Belhadj K; Garderet L; Roussel M; Payen C; Mathiot C; Fermand JP; Meuleman N; Rollet S; Maglio ME; Zeytoonjian AA; Weller EA; Munshi N; Anderson KC; Richardson PG; Facon T; Avet-Loiseau H; Harousseau JL; Moreau P;
    N Engl J Med; 2017 Apr; 376(14):1311-1320. PubMed ID: 28379796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.
    Biran N; Gourna Paleoudis E; Feinman R; Vesole DH; Zenreich J; Wang S; Ahn J; Bansal M; Rowley S; Donato M; Pecora AL; Richter J; Anand P; McBride L; Ivanovski K; Korngold R; Siegel DS
    Am J Hematol; 2021 Nov; 96(11):E430-E433. PubMed ID: 34435374
    [No Abstract]   [Full Text] [Related]  

  • 26. Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.
    Lahoud OB; Landau H; Nguyen J; Devlin S; Lendvai N; Weltz J; Ayorinde T; Chung DJ; Lesokhin AM; Kewalramani T; Korde N; Mailankody S; Landgren O; Giralt S; Comenzo RL; Hassoun H
    Leuk Lymphoma; 2022 Sep; 63(9):2126-2135. PubMed ID: 35648041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance.
    Gaballa MR; Ma J; Tanner MR; Al-Juhaishi T; Bashir Q; Srour SA; Saini NY; Ramdial JL; Nieto Y; Murphy R; Rezvani K; Tang G; Lee HC; Patel KK; Kaufman GP; Manasanch EE; Ullah MR; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Leuk Lymphoma; 2022 Mar; 63(3):710-721. PubMed ID: 34686083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second malignancies in multiple myeloma; emerging patterns and future directions.
    Maclachlan K; Diamond B; Maura F; Hillengass J; Turesson I; Landgren CO; Kazandjian D
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101144. PubMed ID: 32139010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of efficacy, safety, patients' quality of life, and doctors' occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma.
    Xu L; Liu J; Huang B; Kuang L; Gu J; Chen M; Zou W; Li J
    Cancer Med; 2021 Mar; 10(5):1656-1667. PubMed ID: 33527753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
    Diamond B; Maclachlan K; Chung DJ; Lesokhin AM; Ola Landgren C
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101140. PubMed ID: 32139006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone].
    Xu JY; Yan WW; Fan HS; Liu JH; Du CX; Deng SH; Sui WW; Xu Y; Qiu LG; An G
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2338-2344. PubMed ID: 35970791
    [No Abstract]   [Full Text] [Related]  

  • 33. Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.
    Kauer J; Freundt EP; Schmitt A; Weinhold N; Mai EK; Müller-Tidow C; Goldschmidt H; Raab MS; Kriegsmann K; Sauer S
    BMC Cancer; 2023 Nov; 23(1):1132. PubMed ID: 37990162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study.
    Tan TD; Hong YC; Li SS; Yu JT; Sung YC; Wang PN; Teng CJ
    Chin J Physiol; 2020; 63(5):211-217. PubMed ID: 33109787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma.
    Laubach JP; Tuchman SA; Rosenblatt JM; Mitsiades CS; Colson K; Masone K; Warren D; Redd RA; Grayson D; Richardson PG
    Blood Cancer J; 2021 Feb; 11(2):20. PubMed ID: 33563894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
    Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
    Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Murphy S; Lutska Y; Pei H; Ukropec J; Vermeulen J; de Boer C; Hoehn D; Lin TS; Richardson PG
    Blood; 2020 Aug; 136(8):936-945. PubMed ID: 32325490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.
    Chung DJ; Shah N; Wu J; Logan B; Bisharat L; Callander N; Cheloni G; Anderson K; Chodon T; Dhakal B; Devine S; Somaiya Dutt P; Efebera Y; Geller N; Ghiasuddin H; Hematti P; Holmberg L; Howard A; Johnson B; Karagkouni D; Lazarus HM; Malek E; McCarthy P; McKenna D; Mendizabal A; Nooka A; Munshi N; O'Donnell L; Rapoport AP; Reese J; Rosenblatt J; Soiffer R; Stroopinsky D; Uhl L; Vlachos IS; Waller EK; Young JW; Pasquini MC; Avigan D
    Clin Cancer Res; 2023 Dec; 29(23):4784-4796. PubMed ID: 37463058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
    Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.